A carregar...
Cancer therapeutic antibodies come of age: Targeting minimal residual disease
Ten years after the first clinical application of Rituximab, an anti‐CD20 recombinant monoclonal antibody, immunotherapy has become common practice in oncology wards. Thanks to the great diversity of the immune system and the powerful methodology of genetic engineering, the pharmacologic potential o...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5543854/ https://ncbi.nlm.nih.gov/pubmed/19383286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2007.01.003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|